Trials / Completed
CompletedNCT01565330
A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers
An Open Label, Parallel Group, Dose Comparison of Safety and Imaging Characteristics of 111 and 370 MBq (3 and 10 mCi) of 18F-AV-45 for Brain Imaging of Amyloid in Healthy Volunteers and Patients With Alzheimer's Disease (AD)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Avid Radiopharmaceuticals · Industry
- Sex
- All
- Age
- 35 Years
- Healthy volunteers
- Accepted
Summary
This study will test two different doses of florbetapir F 18 to determine which dose is best to image amyloid plaques in the brains of Alzheimer's Disease (AD) patients using a positron emission tomography (PET) scanner.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | florbetapir F 18 | single dose IV injection |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2012-03-28
- Last updated
- 2012-06-18
- Results posted
- 2012-05-02
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01565330. Inclusion in this directory is not an endorsement.